《美股業績》強生(JNJ.US)季度多賺22% 高層暗示裁員
道指成分股,美國健康護理巨擘強生(JNJ.US)公佈第三季度業績。季度純利44.58億美元,按年升22%。每股季度攤薄純利1.68美元,經調整後爲2.55美元,高於市場預期的2.47美元。季度對消費者銷售237.91億美元,按年升2%,高於市場預期的233.4億元。
公司癌症藥Darzalex銷按年升30%至20.52億美元,整個醫藥部門季度銷售按年升3%至132.14億美元,醫療設備銷售按年升2.1%至67.82億美元。消費者健康業務收入按年跌0.4%至37.95億美元。
公司財務總監Joseph Wolk表示,正尋求調整業務規模至合適水平,暗示將會裁員。公司旗下消費者業務明年將分拆爲Kenvue,分拆後公司將集中其餘兩大領域,即醫藥及醫療科技。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.